The core of the collaboration is the use of a generative AI platform for protein engineering, which will be directly integrated into Bayer's existing research and development processes. The aim is to get better molecules into clinical development faster. Fewer optimisation loops, greater efficacy and better manufacturability should increase the probability of success of new antibodies, especially with complex mechanisms of action. After a successful field test, Bayer chose Cradle as its preferred technology partner. The software supports a "lab-in-the-loop" approach in which AI and experimentation work closely together. The two partners are also launching a joint research project in the field of machine learning to further expand their capabilities. The collaboration is exemplary of a change in pharmaceutical research. AI is no longer used selectively, but across entire drug portfolios. For Bayer, this means a further step towards faster development cycles and more effective medicines for patients.
Press release from "Bayer Corporation" dated 7 January 2026